e2f3 Search Results


92
Bioss bs 1722r
Bs 1722r, supplied by Bioss, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e2f3/E2F3+Polyclonal+Antibody/pmc08960645-126-0-1
Average 92 stars, based on 1 article reviews
bs 1722r - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier

94
Genecopoeia paper n a human e2f3 reverse
Paper N A Human E2f3 Reverse, supplied by Genecopoeia, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e2f3/Promoter+reporter+clone+for+Human+E2F3/pm29474920-163-25-72
Average 94 stars, based on 1 article reviews
paper n a human e2f3 reverse - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

93
Proteintech e2f3 primary antibodies
<t>E2F3</t> is a miR-194-5p target gene in TE2 and KYSE150 cells A Predicted partially complementary binding sequence between E2F3 mRNA and miR-194-5p B Dual-luciferase reporter assays confirming miR-194-5p binding to the E2F3 3’UTR. C Pull-down assay was used to confirm the interaction of E2F3 and miR-194-5p D Western blot analysis of E2F3 protein levels in TE2 cells after miR-194-5p overexpression. * P < 0.05
E2f3 Primary Antibodies, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e2f3/E2F3+Antibody/pmc12801454-60-8-11
Average 93 stars, based on 1 article reviews
e2f3 primary antibodies - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology e2f3
FIG. 6. C/EBP regulates the expression of E2F family genes in E-treated uterine epithelial cells. (A) LE cells were isolated from uteri of ovariectomized WT or C/EBP/ mice following treatment with E for 0, 12, and 15 h. (a to c) Expression levels of E2F1 (a), E2F2 (b), and <t>E2F3</t> (c) were determined by real-time PCR. The fold changes indicate mRNA expression levels of the E2F genes relative to those of E-treated WT cells at 0 h. (d) Relative steady-state levels of mRNAs for E2Fs 1, 2, and 3 in primary LE cells obtained from uteri treated with E for 15 h are shown following normalization with the 36B4 mRNA level. Statistically significant differences (P 0.05) are indicated by asterisks. (B) Uteri from WT and C/EBP-null mice treated with E for 15 h were collected, and sections were subjected to IHC analysis using anti-E2F3 antibody. Positive staining for E2F3 is indicated in red, and DAPI-stained nuclei are shown in blue. (C) ChIP analysis. LE cells were isolated from uteri of ovariectomized WT mice following treatment with E for 12 h. ChIP was performed as described in Materials and Methods using antibodies against C/EBP, RNA polymerase II (RNAP II), and rabbit IgG. Relative levels of recruitment at various sites on the E2F3 promoter were determined by real-time PCR and normalized to input DNA and RNA polymerase II values.
E2f3, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e2f3/E2F-3+Antibody/10__1128_slash_mcb__00872___09-84-46-47
Average 93 stars, based on 1 article reviews
e2f3 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

90
OriGene viral infections full length human e2f3 cdna
FIG. 6. C/EBP regulates the expression of E2F family genes in E-treated uterine epithelial cells. (A) LE cells were isolated from uteri of ovariectomized WT or C/EBP/ mice following treatment with E for 0, 12, and 15 h. (a to c) Expression levels of E2F1 (a), E2F2 (b), and <t>E2F3</t> (c) were determined by real-time PCR. The fold changes indicate mRNA expression levels of the E2F genes relative to those of E-treated WT cells at 0 h. (d) Relative steady-state levels of mRNAs for E2Fs 1, 2, and 3 in primary LE cells obtained from uteri treated with E for 15 h are shown following normalization with the 36B4 mRNA level. Statistically significant differences (P 0.05) are indicated by asterisks. (B) Uteri from WT and C/EBP-null mice treated with E for 15 h were collected, and sections were subjected to IHC analysis using anti-E2F3 antibody. Positive staining for E2F3 is indicated in red, and DAPI-stained nuclei are shown in blue. (C) ChIP analysis. LE cells were isolated from uteri of ovariectomized WT mice following treatment with E for 12 h. ChIP was performed as described in Materials and Methods using antibodies against C/EBP, RNA polymerase II (RNAP II), and rabbit IgG. Relative levels of recruitment at various sites on the E2F3 promoter were determined by real-time PCR and normalized to input DNA and RNA polymerase II values.
Viral Infections Full Length Human E2f3 Cdna, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e2f3/E2F3+(NM_001949)+Human+Tagged+ORF+Clone+Lentiviral+Particle/pmc03865059-268-0-8
Average 90 stars, based on 1 article reviews
viral infections full length human e2f3 cdna - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

92
Santa Cruz Biotechnology e2f transcription factor 3 e2f3
Figure 3. <t>E2F3</t> is a direct target of miR‑577. (A) Schematic representation of seven miR‑577 putative target sites in E2F3 3'‑UTR. (B) Western blot analysis of E2F3 protein levels in response to miR‑577 overexpression in HGC‑27 (left) and MKN‑74 (right) cells. GAPDH was used as loading control. Relative luciferase activity of (C) HGC‑27 and (D) MKN‑74 cells transfected with plasmids carrying 3'‑UTR of E2F3 gene and control miRNA, miR‑577 or anti‑miR577. Values are presented as the mean ± standard error of the mean of three independent experiments (n=4). *P<0.05 and **P<0.01 vs. control miRNA. E2F3, <t>E2F</t> transcrip tion factor 3; miR/miRNA, microRNA; UTR, untranslated region.
E2f Transcription Factor 3 E2f3, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e2f3/E2F-3+siRNA/pm26622688-38-0-14
Average 92 stars, based on 1 article reviews
e2f transcription factor 3 e2f3 - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier

90
OriGene full length human e2f3 cdna
Figure 3. <t>E2F3</t> is a direct target of miR‑577. (A) Schematic representation of seven miR‑577 putative target sites in E2F3 3'‑UTR. (B) Western blot analysis of E2F3 protein levels in response to miR‑577 overexpression in HGC‑27 (left) and MKN‑74 (right) cells. GAPDH was used as loading control. Relative luciferase activity of (C) HGC‑27 and (D) MKN‑74 cells transfected with plasmids carrying 3'‑UTR of E2F3 gene and control miRNA, miR‑577 or anti‑miR577. Values are presented as the mean ± standard error of the mean of three independent experiments (n=4). *P<0.05 and **P<0.01 vs. control miRNA. E2F3, <t>E2F</t> transcrip tion factor 3; miR/miRNA, microRNA; UTR, untranslated region.
Full Length Human E2f3 Cdna, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e2f3/E2F3+(NM_001243076)+Human+Tagged+ORF+Clone/pmc03865059-315-0-6
Average 90 stars, based on 1 article reviews
full length human e2f3 cdna - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
OriGene pcmv6 e2f3
Figure 3. <t>E2F3</t> is a direct target of miR‑577. (A) Schematic representation of seven miR‑577 putative target sites in E2F3 3'‑UTR. (B) Western blot analysis of E2F3 protein levels in response to miR‑577 overexpression in HGC‑27 (left) and MKN‑74 (right) cells. GAPDH was used as loading control. Relative luciferase activity of (C) HGC‑27 and (D) MKN‑74 cells transfected with plasmids carrying 3'‑UTR of E2F3 gene and control miRNA, miR‑577 or anti‑miR577. Values are presented as the mean ± standard error of the mean of three independent experiments (n=4). *P<0.05 and **P<0.01 vs. control miRNA. E2F3, <t>E2F</t> transcrip tion factor 3; miR/miRNA, microRNA; UTR, untranslated region.
Pcmv6 E2f3, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e2f3/E2f3+(NM_001137626)+Rat+Untagged+Clone/pmc08302521-114-63-68
Average 90 stars, based on 1 article reviews
pcmv6 e2f3 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Cyagen Biosciences e2f3 protein expression
Figure 3. Luciferase assays. Relative luciferase activity was assessed in bone marrow‑derived mesenchymal stem cells following co‑transfection with miR‑141 and <t>E2F3</t> WT or mut plasmids. **P<0.01 vs. control. miR, microRNA; E2F3, E2F transcription factor 3, NC negative control; WT, wild‑type; mut, mutant.
E2f3 Protein Expression, supplied by Cyagen Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e2f3/E2f3/pm35616132-93-4-18
Average 90 stars, based on 1 article reviews
e2f3 protein expression - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

93
Addgene inc egfp gram w plasmid
Figure 3. Luciferase assays. Relative luciferase activity was assessed in bone marrow‑derived mesenchymal stem cells following co‑transfection with miR‑141 and <t>E2F3</t> WT or mut plasmids. **P<0.01 vs. control. miR, microRNA; E2F3, E2F transcription factor 3, NC negative control; WT, wild‑type; mut, mutant.
Egfp Gram W Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e2f3/pGL3-Control-E2F-3'UTR-WT+(Plasmid+%2321170)/bio_rxiv__2025__06__15__659789-138-1-6
Average 93 stars, based on 1 article reviews
egfp gram w plasmid - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

90
OriGene e2f3
Figure 3. Luciferase assays. Relative luciferase activity was assessed in bone marrow‑derived mesenchymal stem cells following co‑transfection with miR‑141 and <t>E2F3</t> WT or mut plasmids. **P<0.01 vs. control. miR, microRNA; E2F3, E2F transcription factor 3, NC negative control; WT, wild‑type; mut, mutant.
E2f3, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e2f3/E2F3+(NM_001949)+Human+Tagged+ORF+Clone/pmc03302296-57-1-14
Average 90 stars, based on 1 article reviews
e2f3 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

98
Thermo Fisher gene exp e2f3 mm01138833 m1
Figure 3. Luciferase assays. Relative luciferase activity was assessed in bone marrow‑derived mesenchymal stem cells following co‑transfection with miR‑141 and <t>E2F3</t> WT or mut plasmids. **P<0.01 vs. control. miR, microRNA; E2F3, E2F transcription factor 3, NC negative control; WT, wild‑type; mut, mutant.
Gene Exp E2f3 Mm01138833 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e2f3/Gene+Exp%2E+E2f3%2C+Mm01138833_m1/pmc08514096-213-74--1
Average 98 stars, based on 1 article reviews
gene exp e2f3 mm01138833 m1 - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier

Image Search Results


E2F3 is a miR-194-5p target gene in TE2 and KYSE150 cells A Predicted partially complementary binding sequence between E2F3 mRNA and miR-194-5p B Dual-luciferase reporter assays confirming miR-194-5p binding to the E2F3 3’UTR. C Pull-down assay was used to confirm the interaction of E2F3 and miR-194-5p D Western blot analysis of E2F3 protein levels in TE2 cells after miR-194-5p overexpression. * P < 0.05

Journal: World Journal of Surgical Oncology

Article Title: Circ_0001741 regulates proliferation and invasion in ESCC via the miR-194-5p/E2F3 axis

doi: 10.1186/s12957-025-04124-2

Figure Lengend Snippet: E2F3 is a miR-194-5p target gene in TE2 and KYSE150 cells A Predicted partially complementary binding sequence between E2F3 mRNA and miR-194-5p B Dual-luciferase reporter assays confirming miR-194-5p binding to the E2F3 3’UTR. C Pull-down assay was used to confirm the interaction of E2F3 and miR-194-5p D Western blot analysis of E2F3 protein levels in TE2 cells after miR-194-5p overexpression. * P < 0.05

Article Snippet: Membranes were incubated overnight at 4 °C with E2F3 primary antibodies (Proteintech, China, Cat No. 27615-1-AP), followed by HRP-conjugated secondary antibodies (Proteintech, China).

Techniques: Binding Assay, Sequencing, Luciferase, Pull Down Assay, Western Blot, Over Expression

E2F3 overexpression reverses the effects of circ_0001741 knockdown A E2F3 overexpression partially rescues the anti-invasive effects of si-circ_0001741 or miR-194-5p in TE2 and KYSE150 cells B E2F3 overexpression partially restores proliferation suppressed by si-circ_0001741 or miR-194-5p. * P < 0.05

Journal: World Journal of Surgical Oncology

Article Title: Circ_0001741 regulates proliferation and invasion in ESCC via the miR-194-5p/E2F3 axis

doi: 10.1186/s12957-025-04124-2

Figure Lengend Snippet: E2F3 overexpression reverses the effects of circ_0001741 knockdown A E2F3 overexpression partially rescues the anti-invasive effects of si-circ_0001741 or miR-194-5p in TE2 and KYSE150 cells B E2F3 overexpression partially restores proliferation suppressed by si-circ_0001741 or miR-194-5p. * P < 0.05

Article Snippet: Membranes were incubated overnight at 4 °C with E2F3 primary antibodies (Proteintech, China, Cat No. 27615-1-AP), followed by HRP-conjugated secondary antibodies (Proteintech, China).

Techniques: Over Expression, Knockdown

FIG. 6. C/EBP regulates the expression of E2F family genes in E-treated uterine epithelial cells. (A) LE cells were isolated from uteri of ovariectomized WT or C/EBP/ mice following treatment with E for 0, 12, and 15 h. (a to c) Expression levels of E2F1 (a), E2F2 (b), and E2F3 (c) were determined by real-time PCR. The fold changes indicate mRNA expression levels of the E2F genes relative to those of E-treated WT cells at 0 h. (d) Relative steady-state levels of mRNAs for E2Fs 1, 2, and 3 in primary LE cells obtained from uteri treated with E for 15 h are shown following normalization with the 36B4 mRNA level. Statistically significant differences (P 0.05) are indicated by asterisks. (B) Uteri from WT and C/EBP-null mice treated with E for 15 h were collected, and sections were subjected to IHC analysis using anti-E2F3 antibody. Positive staining for E2F3 is indicated in red, and DAPI-stained nuclei are shown in blue. (C) ChIP analysis. LE cells were isolated from uteri of ovariectomized WT mice following treatment with E for 12 h. ChIP was performed as described in Materials and Methods using antibodies against C/EBP, RNA polymerase II (RNAP II), and rabbit IgG. Relative levels of recruitment at various sites on the E2F3 promoter were determined by real-time PCR and normalized to input DNA and RNA polymerase II values.

Journal: Molecular and Cellular Biology

Article Title: Lack of CCAAT Enhancer Binding Protein Beta (C/EBPβ) in Uterine Epithelial Cells Impairs Estrogen-Induced DNA Replication, Induces DNA Damage Response Pathways, and Promotes Apoptosis

doi: 10.1128/mcb.00872-09

Figure Lengend Snippet: FIG. 6. C/EBP regulates the expression of E2F family genes in E-treated uterine epithelial cells. (A) LE cells were isolated from uteri of ovariectomized WT or C/EBP/ mice following treatment with E for 0, 12, and 15 h. (a to c) Expression levels of E2F1 (a), E2F2 (b), and E2F3 (c) were determined by real-time PCR. The fold changes indicate mRNA expression levels of the E2F genes relative to those of E-treated WT cells at 0 h. (d) Relative steady-state levels of mRNAs for E2Fs 1, 2, and 3 in primary LE cells obtained from uteri treated with E for 15 h are shown following normalization with the 36B4 mRNA level. Statistically significant differences (P 0.05) are indicated by asterisks. (B) Uteri from WT and C/EBP-null mice treated with E for 15 h were collected, and sections were subjected to IHC analysis using anti-E2F3 antibody. Positive staining for E2F3 is indicated in red, and DAPI-stained nuclei are shown in blue. (C) ChIP analysis. LE cells were isolated from uteri of ovariectomized WT mice following treatment with E for 12 h. ChIP was performed as described in Materials and Methods using antibodies against C/EBP, RNA polymerase II (RNAP II), and rabbit IgG. Relative levels of recruitment at various sites on the E2F3 promoter were determined by real-time PCR and normalized to input DNA and RNA polymerase II values.

Article Snippet: Sections were incubated with the following primary antibodies diluted in blocking solution (0.25% bovine serum albumin [BSA], 0.3% Triton X-100, sterile PBS) overnight at 4°C: BrdU and Ki67 (BD Pharmingen), phospho-Ser10 histone H3 (Upstate Biotechnology); cyclin E, cyclin A, and Rad18 (Abcam); cyclin D1 (LabVision NeoMarkers); E2F3 (Santa Cruz Biotechnology); p27 (BD Transduction Laboratories); and phospho(Ser1981)-ATM, phospho-(Ser139)-H2AX, caspase 3, and cleaved caspase 3 (Cell Signaling Technology).

Techniques: Expressing, Isolation, Real-time Polymerase Chain Reaction, Staining

FIG. 10. Molecular pathways regulated by C/EBP during E-in- duced proliferation of uterine epithelial cells. In mouse uterine epi- thelial cells, the expression of C/EBP is stimulated by E and opposed by simultaneous treatment with P. C/EBP controls the entry of E- stimulated epithelial cells into the S phase of the cell cycle by upregu- lating the expression of E2F3 and cyclin E. It also promotes the nuclear localization of cyclin E, which enables the formation of an active cyclin E-cdk2 complex critical for DNA replication. The lack of C/EBP allows the nuclear accumulation of p27, which contributes to the cell cycle arrest. In E-stimulated C/EBP-null uterine epithelial cells, stalled DNA replication activates a DNA damage response path- way involving ATM/ATR, Chk1/Chk2, Rad18, and p53. Activated p53 maintains the block in DNA replication by enhancing the synthesis of the cell cycle inhibitor p21 and also promotes the removal of damaged cells via caspase-dependent apoptosis.

Journal: Molecular and Cellular Biology

Article Title: Lack of CCAAT Enhancer Binding Protein Beta (C/EBPβ) in Uterine Epithelial Cells Impairs Estrogen-Induced DNA Replication, Induces DNA Damage Response Pathways, and Promotes Apoptosis

doi: 10.1128/mcb.00872-09

Figure Lengend Snippet: FIG. 10. Molecular pathways regulated by C/EBP during E-in- duced proliferation of uterine epithelial cells. In mouse uterine epi- thelial cells, the expression of C/EBP is stimulated by E and opposed by simultaneous treatment with P. C/EBP controls the entry of E- stimulated epithelial cells into the S phase of the cell cycle by upregu- lating the expression of E2F3 and cyclin E. It also promotes the nuclear localization of cyclin E, which enables the formation of an active cyclin E-cdk2 complex critical for DNA replication. The lack of C/EBP allows the nuclear accumulation of p27, which contributes to the cell cycle arrest. In E-stimulated C/EBP-null uterine epithelial cells, stalled DNA replication activates a DNA damage response path- way involving ATM/ATR, Chk1/Chk2, Rad18, and p53. Activated p53 maintains the block in DNA replication by enhancing the synthesis of the cell cycle inhibitor p21 and also promotes the removal of damaged cells via caspase-dependent apoptosis.

Article Snippet: Sections were incubated with the following primary antibodies diluted in blocking solution (0.25% bovine serum albumin [BSA], 0.3% Triton X-100, sterile PBS) overnight at 4°C: BrdU and Ki67 (BD Pharmingen), phospho-Ser10 histone H3 (Upstate Biotechnology); cyclin E, cyclin A, and Rad18 (Abcam); cyclin D1 (LabVision NeoMarkers); E2F3 (Santa Cruz Biotechnology); p27 (BD Transduction Laboratories); and phospho(Ser1981)-ATM, phospho-(Ser139)-H2AX, caspase 3, and cleaved caspase 3 (Cell Signaling Technology).

Techniques: Expressing, Blocking Assay

Figure 3. E2F3 is a direct target of miR‑577. (A) Schematic representation of seven miR‑577 putative target sites in E2F3 3'‑UTR. (B) Western blot analysis of E2F3 protein levels in response to miR‑577 overexpression in HGC‑27 (left) and MKN‑74 (right) cells. GAPDH was used as loading control. Relative luciferase activity of (C) HGC‑27 and (D) MKN‑74 cells transfected with plasmids carrying 3'‑UTR of E2F3 gene and control miRNA, miR‑577 or anti‑miR577. Values are presented as the mean ± standard error of the mean of three independent experiments (n=4). *P<0.05 and **P<0.01 vs. control miRNA. E2F3, E2F transcrip tion factor 3; miR/miRNA, microRNA; UTR, untranslated region.

Journal: Oncology letters

Article Title: MicroRNA-577 inhibits gastric cancer growth by targeting E2F transcription factor 3.

doi: 10.3892/ol.2015.3390

Figure Lengend Snippet: Figure 3. E2F3 is a direct target of miR‑577. (A) Schematic representation of seven miR‑577 putative target sites in E2F3 3'‑UTR. (B) Western blot analysis of E2F3 protein levels in response to miR‑577 overexpression in HGC‑27 (left) and MKN‑74 (right) cells. GAPDH was used as loading control. Relative luciferase activity of (C) HGC‑27 and (D) MKN‑74 cells transfected with plasmids carrying 3'‑UTR of E2F3 gene and control miRNA, miR‑577 or anti‑miR577. Values are presented as the mean ± standard error of the mean of three independent experiments (n=4). *P<0.05 and **P<0.01 vs. control miRNA. E2F3, E2F transcrip tion factor 3; miR/miRNA, microRNA; UTR, untranslated region.

Article Snippet: E2F transcription factor 3 (E2F3)-small interfering (si)RNA and scrambled control siRNA were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). siRNA and miRNA transfection were performed using Lipofectamine 2000 (Invitrogen Life Technologies) according to the manufacturer's instructions.

Techniques: Western Blot, Over Expression, Control, Luciferase, Activity Assay, Transfection

Figure 4. miR‑577 inhibits gastric cancer cell proliferation by downregulating E2F3. (A) Western blot analysis of E2F3 protein levels in response to E2F3 siRNA in HGC‑27 (left) and MKN‑74 (right) cells. (B) Cell proliferation was determined using MTS assays in HGC‑27 and MKN‑74 cells transfected with control siRNA, E2F3 siRNA and E2F3 siRNA+miR‑577. (C) Cell cycle profiles of control siRNA‑, E2F3 siRNA‑ and E2F3 siRNA+miR‑577‑transfected HGC‑27 and MKN‑74 cells. Values are presented as the mean ± standard error of the mean of three independent experiments (n=4). *P<0.05 vs. control siRNA‑transfected cells. E2F3, E2F transcription factor 3; miR, microRNA; siRNA, small interfering RNA; OD, optical density.

Journal: Oncology letters

Article Title: MicroRNA-577 inhibits gastric cancer growth by targeting E2F transcription factor 3.

doi: 10.3892/ol.2015.3390

Figure Lengend Snippet: Figure 4. miR‑577 inhibits gastric cancer cell proliferation by downregulating E2F3. (A) Western blot analysis of E2F3 protein levels in response to E2F3 siRNA in HGC‑27 (left) and MKN‑74 (right) cells. (B) Cell proliferation was determined using MTS assays in HGC‑27 and MKN‑74 cells transfected with control siRNA, E2F3 siRNA and E2F3 siRNA+miR‑577. (C) Cell cycle profiles of control siRNA‑, E2F3 siRNA‑ and E2F3 siRNA+miR‑577‑transfected HGC‑27 and MKN‑74 cells. Values are presented as the mean ± standard error of the mean of three independent experiments (n=4). *P<0.05 vs. control siRNA‑transfected cells. E2F3, E2F transcription factor 3; miR, microRNA; siRNA, small interfering RNA; OD, optical density.

Article Snippet: E2F transcription factor 3 (E2F3)-small interfering (si)RNA and scrambled control siRNA were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). siRNA and miRNA transfection were performed using Lipofectamine 2000 (Invitrogen Life Technologies) according to the manufacturer's instructions.

Techniques: Western Blot, Transfection, Control, Small Interfering RNA

Figure 3. Luciferase assays. Relative luciferase activity was assessed in bone marrow‑derived mesenchymal stem cells following co‑transfection with miR‑141 and E2F3 WT or mut plasmids. **P<0.01 vs. control. miR, microRNA; E2F3, E2F transcription factor 3, NC negative control; WT, wild‑type; mut, mutant.

Journal: Molecular medicine reports

Article Title: MicroRNA‑141 inhibits the differentiation of bone marrow‑derived mesenchymal stem cells in steroid‑induced osteonecrosis via E2F3.

doi: 10.3892/mmr.2022.12750

Figure Lengend Snippet: Figure 3. Luciferase assays. Relative luciferase activity was assessed in bone marrow‑derived mesenchymal stem cells following co‑transfection with miR‑141 and E2F3 WT or mut plasmids. **P<0.01 vs. control. miR, microRNA; E2F3, E2F transcription factor 3, NC negative control; WT, wild‑type; mut, mutant.

Article Snippet: Western blot analysis of E2F3 protein expression. at day 3, 7 and 14, after discarding the RASMX‐90021 medium (Cyagen; cat. no. RASMX‐90021) and α‐MEM (HyClone; Cytiva; SH30265) the cells were lysed in RIPA lysis buffer at 4 ̊C overnight.

Techniques: Luciferase, Activity Assay, Control, Negative Control, Mutagenesis

Figure 4. MRNA expression of miR‑141 and E2F3 (A) Expression levels of miR‑141 in group of control and ONFH at 3d, 7d and 14d. (B) MRNA expression levels of E2F3 in group of NC, miR‑141, ONFH+ inhibitor NC and ONFH+ miR‑141 inhibitor (left part). mRNA expression levels of E2F3 in group of control and ONFH at 3d, 7d and 14d (right part). *P<0.05, **P<0.01 vs. control. miR, microRNA; E2F3, E2F transcription factor 3, NC negative control; ONFH, osteonecrosis of the femoral head.

Journal: Molecular medicine reports

Article Title: MicroRNA‑141 inhibits the differentiation of bone marrow‑derived mesenchymal stem cells in steroid‑induced osteonecrosis via E2F3.

doi: 10.3892/mmr.2022.12750

Figure Lengend Snippet: Figure 4. MRNA expression of miR‑141 and E2F3 (A) Expression levels of miR‑141 in group of control and ONFH at 3d, 7d and 14d. (B) MRNA expression levels of E2F3 in group of NC, miR‑141, ONFH+ inhibitor NC and ONFH+ miR‑141 inhibitor (left part). mRNA expression levels of E2F3 in group of control and ONFH at 3d, 7d and 14d (right part). *P<0.05, **P<0.01 vs. control. miR, microRNA; E2F3, E2F transcription factor 3, NC negative control; ONFH, osteonecrosis of the femoral head.

Article Snippet: Western blot analysis of E2F3 protein expression. at day 3, 7 and 14, after discarding the RASMX‐90021 medium (Cyagen; cat. no. RASMX‐90021) and α‐MEM (HyClone; Cytiva; SH30265) the cells were lysed in RIPA lysis buffer at 4 ̊C overnight.

Techniques: Expressing, Control, Negative Control

Figure 5. Protein expression levels of E2F3. (A) Protein expression of E2F3 in BMSCs from the control or ONFH rat at day 3, 7 and 14. (B) Protein expression of E2F3 in BMSCs from the normal rat transduced with NC or miR‑141 mimic lentivirus and BMSCs from the ONFH rat transduced with the inhibitor NC or miR‑141 inhibitor lentivirus. *P<0.05, **P<0.01 vs. control. miR, microRNA; E2F3, E2F transcription factor 3, NC negative control; ONFH, osteonecrosis of the femoral head; BMSCs, bone marrow‑derived mesenchymal stem cells.

Journal: Molecular medicine reports

Article Title: MicroRNA‑141 inhibits the differentiation of bone marrow‑derived mesenchymal stem cells in steroid‑induced osteonecrosis via E2F3.

doi: 10.3892/mmr.2022.12750

Figure Lengend Snippet: Figure 5. Protein expression levels of E2F3. (A) Protein expression of E2F3 in BMSCs from the control or ONFH rat at day 3, 7 and 14. (B) Protein expression of E2F3 in BMSCs from the normal rat transduced with NC or miR‑141 mimic lentivirus and BMSCs from the ONFH rat transduced with the inhibitor NC or miR‑141 inhibitor lentivirus. *P<0.05, **P<0.01 vs. control. miR, microRNA; E2F3, E2F transcription factor 3, NC negative control; ONFH, osteonecrosis of the femoral head; BMSCs, bone marrow‑derived mesenchymal stem cells.

Article Snippet: Western blot analysis of E2F3 protein expression. at day 3, 7 and 14, after discarding the RASMX‐90021 medium (Cyagen; cat. no. RASMX‐90021) and α‐MEM (HyClone; Cytiva; SH30265) the cells were lysed in RIPA lysis buffer at 4 ̊C overnight.

Techniques: Expressing, Control, Transduction, Negative Control